Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells

Microbial Cell Factories

Volumn 15, Issue 1, 2016, Pages

  Souza, Bianca Mendes ^a   Preisser, Tatiane Melo ^a   Pereira, Vanessa Bastos ^a   Zurita Turk, Meritxell ^a   Castro, Camila Prósperi ^a   Cunha, Vanessa Pecini ^a   Oliveira, Rafael Pires ^b   Gomes Santos, Ana Cristina ^a   Faria, Ana Maria Caetano ^a   Machado, Denise Carmona Cara ^a   Chatel, Jean Marc ^c   Azevedo, Vasco Ariston de Carvalho ^a   Langella, Philippe ^c   Miyoshi, Anderson ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO FEDERAL DO PARANÁ   (Brazil)

^c UMR1319 MICALIS   (France)

Author keywords

Crohn's disease; Interleukin 10; Interleukin 4; Lactococcus lactis; Regulatory cells

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID; CYTOKINE; DNA; IL10 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CHO CELL LINE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; LACTOCOCCUS LACTIS; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; ULCERATIVE COLITIS; ANIMAL; CHEMICALLY INDUCED; CRICETULUS; CYTOLOGY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; MUCOSA; SECRETION (PROCESS); ULTRASTRUCTURE;

ANIMALS; CHO CELLS; CRICETULUS; CYTOKINES; DNA; GENETIC VECTORS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTERLEUKIN-4; INTESTINAL MUCOSA; LACTOCOCCUS LACTIS; MICE; MUCOUS MEMBRANE; TRANSFECTION;

EID: 84984636086     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/s12934-016-0548-x     Document Type: Article

References (61)

1. Sventoraityte J, Zvirbliene A, Kiudelis G, et al. Immune system alterations in patients with inflammatory bowel disease during remission. Medicina (Kaunas). 2008;44:27-33.
2. Neuman MG. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol. 2004;13:309-16.
3. Reiff C, Kelly D. Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol. 2010;300:25-33.
4. Peloquin JM, Nguyen DD. The microbiota and inflammatory bowel disease: insights from animal models. Anaerobe. 2013;24:102-6.
5. Yamamoto T. Nutrition and diet in inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29:216-21.
6. Holland N, Dong J, Garnett E, et al. Reduced intracellular T-helper 1 interferon-gamma in blood of newly diagnosed children with Crohn's disease and age-related changes in Th1/Th2 cytokine profiles. Pedriatr Res. 2008;63:257-62.
7. Rogy MA, Beinhauer BG, Reinisch W, et al. Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum Gene Ther. 2000;11:1731-41.
8. Schoffen JPF, Prado IMM. Aspectos epidemiológicos e etiológicos da doença de Crohn. Revista Saúde e Pesquisa. 2011;4:73-80.
9. Actis GC, Rosina F. Inflammatory bowel disease: an archetype disorder of outer environment sensor systems. World J Gastrointest Pharmacol Ther. 2013;4:41-6.
10. Chowers Y. Taking Crohn's disease personally. Rambam Maimonides Med J. 2013;4:e0011.
11. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-21.
12. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 1991;77:1859-70.
13. Luzina IG, Keegan AD, Heller NM, et al. Regulation of inflammation by interleukin-4: a review of "alternatives". J Leukoc Biol. 2012;92(753):64.
14. Finkelman FD, Urban JF Jr. The other side of the coin: the protective role of the TH2 cytokines. J Allergy Clin Immunol. 2001;107:772-80.
15. Oliphant CJ, Barlow JL, McKenzie AN. Insights into the initiation of type 2 immune responses. Immunology. 2011;134:378-85.
16. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593-604.
17. Li Z, Zhang Y, Sun B. Current understanding of Th2 cell differentiation and function. Protein Cell. 2011;2:604-11.
18. Hogaboam CM, Vallance BA, Kumar A, et al. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest. 1997;100:2766-76.
19. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117:1162-72.
20. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14:4280-8.
21. Xiong J, Lin YH, Bi LH, et al. Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis. BMC Gastroenterol. 2013;13:165.
22. Innocentin S, Guimarães V, Miyoshi A, et al. Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells. Appl Environ Microbiol. 2009;75:4870-8.
23. Pontes D, Innocentin S, Del Carmen S, et al. Production of fibronectin binding protein A at the surface of Lactococcus lactis increases plasmid transfer in vitro and in vivo. PLoS One. 2012;7:e44892.
24. Del Carmen S, Zurita-Turk M, Lima FA, et al. A novel interleukin-10 DNA mucosal delivery system attenuates intestinal inflammation in a mouse model. Eur J Inflamm. 2013;11:641-54.
25. Guimarães V, Innocentin S, Chatel JM, et al. A new plasmid vector for DNA delivery using lactococci. Genet Vaccines Ther. 2009;7:4.
26. Dean DA. Import of plasmid DNA into the nucleus is sequence specific. Exp Cell Res. 1997;230:293-302.
27. Vacik J, Dean BS, Zimmer WE, et al. Cell-specific nuclear import of plasmid DNA. Gene Ther. 1999;6:1006-14.
28. Que YA, Francois P, Haefliger JA, et al. Reassessing the role of Staphylococcus aureus clumping factor and fibronecting-binding protein by expression in Lactococcus lactis. Infect Immun. 2001;69:6296-302.
29. Reece-Hoyes JS, Walhout AJM. Cloning and transformation with plasmid vectors. In: Green MR, Sambrook J, editors. Molecular cloning: a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory; 2012. p. 177-82.
30. Langella P, Le Loir Y, Ehrlich SD, et al. Efficient plasmid mobilization by pIP501 in Lactococcus lactis subsp. lactis. J Bacteriol. 1993;175:5806-13.
31. Cenac N, Coelho AM, Nguyen C, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol. 2002;161:1903-15.
32. Ameho CK, Adjei AA, Harrison EK, et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor α production in trinitrobenzene sulphonic acid induced colitis. Gut. 1997;41:487-93.
33. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000;6:583-8.
34. Jones-Hall YL, Grisham MB. Immunopathological characterization of selected mouse models of inflammatory bowel disease: comparison to human disease. Pathophysiology. 2014;21:267-88.
35. Hurst SM, Wilkinson TS, McLoughlin RM, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705-14.
36. Kaplasnki G, Marin V, Montero-Julian F, et al. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003;24(25):9.
37. Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:382-8.
38. Waldner MJ, Neurath MF. Master regulator of intestinal disease: iL-6 in chronic inflammation and cancer development. Semin Immunol. 2014;26:75-9.
39. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629-36.
40. Kitani A, Fuss IJ, Nakamura K, et al. Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-β1 plasmid: TGF-β1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor β2 chain downregulation. J Exp Med. 2000;192:41-52.
41. Fuss IJ, Boirivant M, Lacy B, et al. The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. J Immunol. 2002;168:900-8.
42. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol. 2008;8:421-34.
43. Alexander KL, Targan SR, Elson CO. Microbiota activation and regulation of innate and adaptive immunity. Immunol Rev. 2014;260:206-20.
44. Levings MK, Schrader JW. IL-4 inhibits the production of TNF-α and IL-12 by STAT6-dependent and -independent mechanisms. J Immunol. 1999;162:5224-9.
45. Neurath MF, Weigmann B, Finotto F, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med. 2002;195:1129-43.
46. Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science. 2001;292:1907-10.
47. Neurath MG, Finotto F, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med. 2002;8:567-73.
48. te Velde AA, Verstege MI, Hommes DW. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:995-9.
49. Yamamoto M, Yoshizaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol. 2000;164:4878-82.
50. Jin Y, Lin Y, Lin L, et al. IL-17/INF-γ interactions regulate intestinal inflammation in TNBS-induced acute colitis. J Interferon Cytokine Res. 2012;32:548-56.
51. Magan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-β induces development of the T(H)17 lineage. Nature. 2006;441:231-4.
52. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
53. Zurita-Turk M, Del Carmen S, Santos AC, et al. Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis. BMC Biotechnol. 2014;14:73.
54. Mowat AM, Bain CC. Mucosal macrophages in intestinal homeostasis and inflammation. J Innate Immun. 2011;3:550-64.
55. Bain CC, Mowat AM. The monocyte-macrophage axis in the intestine. Cell Immunol. 2014;291:41-8.
56. Bain CC, Mowat AM. Macrophages in intestinal homeostasis and inflammation. Immunol Rev. 2014;260:102-17.
57. Mosser MD, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958-69.
58. Strober W, Lúdvíksson BR, Fuss IJ. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease. Ann Intern Med. 1998;128:848-56.
59. Pontes DS, de Azevedo MS, Chatel JM, et al. Lactococcus lactis as a live vector: heterologous protein production and DNA delivery systems. Protein Expr Purif. 2011;79:165-75.
60. Lyamina SV, Kruglov SV, Vedenikin TY, et al. Alternative reprogramming of M1/M2 phenotype of mouse peritoneal macrophages in vitro with interferon-γ and interleukin-4. Bull Exp Biol Med. 2012;152:548-51.
61. Mantovani A. Macrophage diversity and polarization: in vivo veritas. Blood. 2006;108:408-9.